cervical cancer
Conditions
Interventions
Interventions group:Sequential camrelizumab combined with apatinib after radical radiotherapy
Sponsors
CAS Hefei Cancer Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Pathologically diagnosed as cervical squamous cell carcinoma. 2. Age > 18 years old. 3. Locally advanced cervical squamous cell carcinoma at FIGO 2018 stage ? - ?A. 4. No history of radical radiotherapy in the past. 5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 - 1. 6. PD-L1 >= 1%; Or PD-L1 expression negative 7. Before treatment, there are no significant abnormalities in white blood cells, red blood cells, platelets, hemoglobin, liver and kidney functions, coagulation function, cardiopulmonary function, etc., and the patient is expected to tolerate radiotherapy and chemotherapy. 8. Signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Synchronous double primary malignant tumors; other pathological types such as adenocarcinoma, small - cell carcinoma, sarcoma, etc. 2. History of previous radiotherapy and chemotherapy. 3. Poor patient compliance, failure to return for regular follow - up or receive treatment on schedule. 4. Suffering from autoimmune diseases such as rheumatoid arthritis, ulcerative colitis; infectious diseases such as active hepatitis, pulmonary tuberculosis, etc. 5. Abnormal coagulation function with a bleeding tendency; history of thromboembolic events within 1 year. 6. Cardiopulmonary function is not expected to tolerate radiotherapy and chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progress free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Objective Response Rate;Disease Control Rate;Duration of continuous;Safety; | — |
Countries
China
Contacts
Public ContactXiaotao Qian
CAS Hefei Cancer Hospital
Outcome results
None listed